Three weeks ago, I posted a graph of the cumulative investment of NIGMS Recovery Act funds as a function of the award start date. Below is an updated version.
This graph differs from my previous one in two ways. First, it is up to date as of yesterday. Second, it includes commitments for the second year of awarded 2-year R01 grants. As it shows, we are close to allocating half of our $505 million of Recovery Act funds. We are making more awards every day, with the Challenge grants, GO grants, and faculty start-up (P30) grants to be awarded soon.
The awards made to date can be broken down into seven major categories.
This graph shows the amount and total number of awards (blue type above each bar) in each category. The gray-shaded area over the R01 category reflects second-year commitments.
To put these figures in context, NIGMS currently supports approximately 3,600 R01 grants; 50 AREA (R15) grants; 250 Minority Biomedical Research Support (MBRS) S06, SC1, SC2, SC3, and R25 grants; 50 Minority Access to Research Careers (MARC) T34 grants; and 300 institutional research training T32 grants.
We will continue to update you on our Recovery Act activities as we move from one fiscal year to the next at the end of this month.
Thank you for the update, Jeremy. I’m curious as to where SBIR/STTR grants fall in your breakdown, as they seem to be MIA. Also, 50% of the way when the fiscal year ends in a couple weeks does not seem like “on-track.” Will all FY09 ARRA awards be made before 9/30/09? I look forward to your answers.
To date, NIGMS has made 6 SBIR-STTR supplement awards totaling $1.7 million. NIH-wide more than 100 SBIR-STTR awards have been made totaling over $20 million. You can see details for these awards using NIH RePORTER –click the “NIH Recovery Act Projects” box and select SBIR-STTR under “Funding Mechanism.”
What is an R01 “equivalent” supplement? (important as this is by far the highest number of grants category in the bar graph)
The category “R01 equivalents” includes R37 (MERIT) awards. The 511 R01 equivalent supplements listed include 502 R01 supplements and 9 R37 supplements.
It is not clear to me where in the histogram are recorded the ARRA “Administrative Supplements” made to ongoing R01 grants. Where are those data? Thanks.
Almost all of the awards in the “R01 equivalent supplements” bar are administrative supplements made to ongoing R01 grants.
Does this indicate that most of the ARRA” Administrative supplements for RO1’s have already been awarded and that if you haven’t heard about your supplement request, it probably won’t be funded?
As of the date of my post, slightly less than half of the NIGMS ARRA funds had been awarded. We will be making many additional awards, including administrative supplements, before the end of this fiscal year (September 30). We will also be funding additional administrative supplements in fiscal year 2010. This means that even if you have not received any information about the status of a request you submitted for an administrative supplement, the supplement may still be awarded. We are trying to inform each applicant as soon as we make a definitive decision about his or her request.
Has NIGMS begun to request JIT information from likely Challenge Grants awardees?
And will NIGMS fund additional RC1 Challenge Grants from its own Recovery Act funds?
We have been requesting just-in-time information for Challenge (RC1) grants. As noted in a previous post, NIGMS does plan to invest some (approximately $15M) of our Recovery Act funds in Challenge Grants in addition to those funded by the Office of the Director.
What’s the percentage of the RC1 applications does NIGMS plan to support in addition to those funded by the Office of the Director?
As noted in a news release, NIH received over 20,000 RC1 applications. Approximately 7% of these were assigned to NIGMS. As I indicated, NIGMS plans to invest approximately $15 million in RC1 awards, leading to approximately 15 awards. Thus, we will fund approximately 1% of the RC1 applications that we received (in addition to those funded by the Office of the Director).